Metastatic Colorectal Cancer Pipeline Analysis: 140+ Companies are Working to Improve the Treatment Space | DelveInsight

October 12 21:03 2022
Metastatic Colorectal Cancer Pipeline Analysis: 140+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 140+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • DelveInsight’s Metastatic Colorectal Cancer Pipeline report depicts a robust space with 140+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
  • The leading Metastatic Colorectal Cancer includes G1 Therapeutics, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Celyad Oncology SA, Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences Inc., Merck, Array BioPharma, Sumitomo Dainippon Pharma Co., Ltd, Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, Henlix Biotech, Scandion Oncology A/S, AB Science, Aadi, LLC, Novartis, Roche, Celyad Oncology SA, Boehringer Ingelheim, Amgen, Isofol Medical, Treos Bio Zrt, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, and others are developing potential drug candidates to improve the Metastatic Colorectal Cancer treatment scenario.
  • The promising Metastatic Colorectal Cancer therapies in the pipeline includes CMAB009, Trifluridin/Tipiracil, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, and others
  • Corsela (Trilaciclib) is a small-molecule, short-acting, inhibitor of cyclin-dependent kinases (CDK) 4 and 6 developed by G1 Therapeutics for its myeloprotection and potential antitumor efficacy and safety benefits in combination with cancer chemotherapy. CDKs govern cell cycle progression, and trilaciclib induces a transient, reversible G1 cell cycle arrest of proliferating hematopoietic stem and progenitor cells in bone marrow, thus protecting them from damage during chemotherapy.
  • Famitinib is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs, dysregulated in a variety of tumors, including stem cell factor receptor (c-Kit; SCFR), vascular endothelial growth factor receptor (VEGFR) 2 and 3, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinases Flt1 and Flt3. Inhibition of these RTKs may result in an inhibition of tumor growth and angiogenesis, and eventually tumor regression in tumor cells overexpressing these RTKs. Famitinib is being evaluated in Phase III clinical trial to treat metastatic colorectal cancer.

 

Get an overview of the pipeline landscape @ Metastatic Colorectal Cancer Pipeline Outlook

 

Metastatic Colorectal Cancer Overview

Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. Common sites of distant metastasis are the liver and the peritoneum. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor. CRC that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).

The most common site of metastases for colon or rectal cancer is the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. Approximately one-fifth of CRC cases are metastatic at the time of diagnosis. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC. Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is. There are different types of polyps.

 

Latest Breakthroughs and Developments in the Metastatic Colorectal Cancer Treatment Landscape

  • On November 18, 2021 Gilead Sciences announced that it had exercised its options to three of Arcus Biosciences’ programs. Two are anti-TIGIT molecules, domvanalimab and AB308, and the other is etrumadenant and quemliclustat. The two companies have also added a research collaboration deal. Arcus shares popped 15% at the news.
  • In September 2021, Erasca, announced a clinical trial collaboration and supply agreement with Pfizer Inc. for the BRAF inhibitor encorafenib (BRAFTOVI®). This agreement will support a clinical proof-of-concept study evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E-mutant mCRC.
  • In December 2021, Rottapharm Biotech announced a clinical collaboration with Agenus’ balstilimab (anti-PD-1) in collaboration with its lead candidate CR6086 in advanced colorectal cancer at the National Cancer Institute. Rottapharm Biotech’s clinical collaboration with Agenus offers a promising new combination therapy for patients with advanced pMMR/MSS mCRC where there is a high unmet need, and for a further range of potential applications in other immunotherapy-resistant tumors.
  • On 11 May 2021, Shanghai Henlius Biotech and NeuPharma entered into a drug technology license agreement. NeuPharma will grant the Company a sublicensable exclusive license for related licensed patents and licensed know-how necessary or reasonably useful for the Company to research, develop, produce and commercialize the Licensed Product within the Licensed Territory (China).
  • In November 2021, The US FDA granted a fast track designation to arfolitixorin as a potential therapeutic option for patients with metastatic colorectal cancer (mCRC). This serves as a strong external validation of arfolitixorin’s potential to benefit patients with this devastating disease.
  • In January 2022, Gritstone bio, Inc. announced that the first patient was enrolled for inclusion in the Phase 2/3 GRANITE-CRC-1L trial. The trial evaluates the individualized neoantigen vaccine GRANITE in combination with immune checkpoint blockade for the first line (1L) maintenance treatment of newly diagnosed patients with metastatic, microsatellite-stable colorectal cancer (MSS-CRC). This trial has registrational intent and has been discussed previously with the FDA.

 

Metastatic Colorectal Cancer Emerging Drugs

  • Trilaciclib: G1 Therapeutics
  • Famitinib: Jiangsu Hengrui Medicine
  • CMAB009: Mabpharm Limitied
  • Trastuzumab Deruxtecan: Daiichi Sankyo
  • SCO-101: Scandion Oncology
  • BEY 1107: BeyondBio
  • Etrumadenant: Arcus Biosciences

 

Get to know more information about Metastatic Colorectal Cancer treatment therapies @ Metastatic Colorectal Cancer Clinical Trials

 

Metastatic Colorectal Cancer Pipeline Therapeutics Analysis

There are approx. 140+ key companies which are developing therapies for Metastatic Colorectal cancer. The companies which have their Metastatic Colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, G1 Therapeutics.

 

DelveInsight’s Metastatic Colorectal Cancer Pipeline Report covers around 140+ products under different phases of clinical development like-

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Discover more about therapy set to grab substantial Metastatic Colorectal Cancer Pipeline landscape @ Metastatic Colorectal Cancer Market Drivers and Barriers

 

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Metastatic Colorectal Cancer Companies– G1 Therapeutics, Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Celyad Oncology SA, Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences Inc., Merck, Array BioPharma, Sumitomo Dainippon Pharma Co., Ltd, Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd, Henlix Biotech, Scandion Oncology A/S, AB Science, Aadi, LLC, Novartis, Roche, Celyad Oncology SA, Boehringer Ingelheim, Amgen, Isofol Medical, Treos Bio Zrt, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, and others are developing potential drug candidates to improve the Metastatic Colorectal Cancer treatment scenario.
  • Metastatic Colorectal Cancer therapies– CMAB009, Trifluridin/Tipiracil, Pembrolizumab, Binimetinib, Oxaliplatin, FOLFIRI, FOLFOX, Bevacizumab, and others
  • Hepatitis A Therapeutic Assessment by Product Type
  • Metastatic Colorectal Cancer Therapeutic Assessment by Stage and Product Type
  • Metastatic Colorectal Cancer Therapeutic Assessment by Route of Administration
  • Metastatic Colorectal Cancer Therapeutic Assessment by Stage and Route of Administration
  • Metastatic Colorectal Cancer Therapeutic Assessment by Molecule Type
  • Metastatic Colorectal Cancer Therapeutic Assessment by Stage and Molecule Type
  • Metastatic Colorectal Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
  • Metastatic Colorectal Cancer – Market Drivers and Barriers

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic Colorectal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic Colorectal cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Trilaciclib: G1 Therapeutics
  9. Mid Stage Products (Phase II/III)
  10. SHR 1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
  11. Mid Stage Products (Phase II)
  12. Trastuzumab Deruxtecan: Daiichi Sankyo
  13. Early Stage Products (Phase I/II)
  14. NKTR-255: Nektar Therapeutics
  15. Early Stage Products (Phase I)
  16. Talimogene Laherparepvec: Amgen
  17. Preclinical and Discovery Stage Products
  18. PCS11T: Processa Pharmaceuticals
  19. Inactive Products
  20. Metastatic Colorectal cancer Key Companies
  21. Metastatic Colorectal cancer Key Products
  22. Metastatic Colorectal cancer- Unmet Needs
  23. Metastatic Colorectal cancer- Market Drivers and Barriers
  24. Metastatic Colorectal cancer- Future Perspectives and Conclusion
  25. Metastatic Colorectal cancer Analyst Views
  26. Metastatic Colorectal cancer Key Companies
  27. Appendix

 

Got Queries? Reach out for more information on the Metastatic Colorectal cancer Pipeline Report- Metastatic Colorectal cancer Pipeline Therapeutic Assessment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: